









Markets
/
Stocks
/
nasdaq-kymr
/

Kymera Therapeutics Inc

KYMR

78.160USD

-2.020-2.52%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

3.37BMarket Cap

LossP/E TTM



Kymera Therapeutics Inc

78.160

-2.020-2.52%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kymera Therapeutics Inc

Currency: USD Updated: 2026-03-26

Key Insights

Kymera Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 60 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 118.85.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kymera Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

60 / 391

Overall Ranking

160 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Kymera Therapeutics Inc Highlights

StrengthsRisks

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

Growing

The company is in a growing phase, with the latest annual income totaling USD 39.21M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 39.21M.

Undervalued

The company’s latest PE is -21.76, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 86.46M shares, increasing 3.46% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 30.57K shares of this stock.

Analyst Rating

Based on 23 analysts

Buy

Current Rating

118.850

Target Price

+59.70%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of Kymera Therapeutics Inc is 5.96, ranking 305 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.87M, representing a year-over-year decrease of 61.18%, while its net profit experienced a year-over-year decrease of 22.94%.

Score

Industry at a Glance

Previous score

5.96

Change



Financials

8.19

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.29

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Kymera Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of Kymera Therapeutics Inc is 6.84, ranking 212 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -21.76, which is -82.40% below the recent high of -3.83 and -20.06% above the recent low of -26.12.

Score

Industry at a Glance

Previous score

6.84

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 60/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of Kymera Therapeutics Inc is 8.70, ranking 71 out of 391 in the Biotechnology & Medical Research industry. The average price target is 90.50, with a high of 138.00 and a low of 65.00.

Score

Industry at a Glance

Previous score

8.70

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 23 analysts

Buy

Current Rating

118.850

Target Price

+59.70%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Kymera Therapeutics Inc

KYMR

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of Kymera Therapeutics Inc is 7.22, ranking 107 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 91.68 and the support level at 71.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.01

Change

0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.927

Sell

RSI(14)

44.936

Neutral

STOCH(KDJ)(9,3,3)

56.012

Buy

ATR(14)

4.062

High Vlolatility

CCI(14)

-15.697

Neutral

Williams %R

64.359

Sell

TRIX(12,20)

-0.337

Sell

StochRSI(14)

72.233

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

77.730

Buy

MA10

78.608

Sell

MA20

81.166

Sell

MA50

80.002

Sell

MA100

76.375

Buy

MA200

62.387

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Kymera Therapeutics Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 108.36%, representing a quarter-over-quarter decrease of 3.14%. The largest institutional shareholder is The Vanguard, holding a total of 6.26M shares, representing 7.66% of shares outstanding, with 4.47% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

10.66M

+60.31%

Fidelity Management & Research Company LLC

5.88M

+8.23%

Avoro Capital Advisors LLC

6.35M

-3.14%

The Vanguard Group, Inc.

Star Investors

5.41M

-3.53%

T. Rowe Price Associates, Inc.

Star Investors

5.04M

-25.96%

BVF Partners L.P.

5.50M

Atlas Venture

4.90M

Wellington Management Company, LLP

5.20M

-3.28%

BlackRock Institutional Trust Company, N.A.

3.72M

+5.83%

Invus Public Equities Advisors, LLC

3.43M

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Kymera Therapeutics Inc is 4.36, ranking 88 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.